Press Releases April 1, 2026 08:00 PM

Astera Labs Announces Conference Call to Review First Quarter 2026 Financial Results

Astera Labs schedules Q1 2026 earnings release and conference call to discuss financial results.

By Priya Menon
Share
Twitter Reddit Facebook LinkedIn
ALAB

Astera Labs, a semiconductor-based connectivity solutions provider for rack-scale AI infrastructure, announced it will release its Q1 2026 financial results after market close on May 5, 2026, followed by a conference call hosted by top executives to discuss the results and company outlook.

Astera Labs Announces Conference Call to Review First Quarter 2026 Financial Results
ALAB
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Astera Labs specializes in semiconductor connectivity solutions targeting AI infrastructure, integrating technologies like CXL, Ethernet, NVLink Fusion, and PCIe.
  • The company collaborates with hyperscalers and ecosystem partners to enhance AI infrastructure scalability and flexibility.
  • Their Intelligent Connectivity Platform combined with proprietary software aims to unify diverse systems for improved rack-scale AI performance.

SANTA CLARA, Calif., April 02, 2026 (GLOBE NEWSWIRE) -- Astera Labs, Inc. (Nasdaq: ALAB), a leader in semiconductor-based connectivity solutions for rack-scale AI infrastructure, today announced that it will release its financial results for the first quarter 2026 after the close of market on Tuesday, May 5, 2026. Astera Labs will host a corresponding conference call at 1:30 p.m. Pacific Time, 4:30 p.m. Eastern Time.

Conference Call Details
Date:May 5, 2026Time:1:30 pm PT / 4:30 pm ETHosts:Jitendra Mohan, Chief Executive Officer Sanjay Gajendra, President and Chief Operating Officer Des Lynch, Chief Financial Officer  Dial-in:(800) 715-9871 Conference ID: 5908687Webcast:https://ir.asteralabs.com  

About Astera Labs
Astera Labs (NASDAQ: ALAB) provides rack-scale AI infrastructure through purpose-built connectivity solutions. By collaborating with hyperscalers and ecosystem partners, Astera Labs enables organizations to unlock the full potential of modern AI. Astera Labs’ Intelligent Connectivity Platform integrates CXL®, Ethernet, NVLink Fusion, PCIe®, and UALink™ semiconductor-based technologies with the company’s COSMOS software suite to unify diverse components into cohesive, flexible systems that deliver end-to-end scale-up, and scale-out connectivity. The company’s custom connectivity solutions business complements its standards-based portfolio, enabling customers to deploy tailored architectures to meet their unique infrastructure requirements. Discover more at www.asteralabs.com.

© Astera Labs, Inc.  Astera Labs, and its stylized logo, are trademarks of Astera Labs, Inc. or its affiliates. Other names and brands may be claimed as the property of others.

Investor Contact:
Leslie Green
[email protected]


Risks

  • The report does not disclose expected financial performance, leaving uncertainty about revenue growth or profitability that may impact investor sentiment.
  • Market demand for AI infrastructure solutions can be volatile and dependent on adoption rates in AI and data center sectors.
  • Competition in semiconductor connectivity and AI infrastructure markets is intense, posing risks to market share and margins.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026